达妥木单抗在多发性骨髓瘤一线治疗中的应用进展

doi:10.16150/j.1671-2870.2021.06.015

摘要/Abstract

关键词: 多发性骨髓瘤, 达妥木单抗, 浆细胞, 自体干细胞移植, 完全缓解, 输注反应

中图分类号:

R735

寇明坤, 徐娜娜, 石静云, 吴涛. 达妥木单抗在多发性骨髓瘤一线治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(06): 588-591.

参考文献 31

[1]	Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma[J]. Blood Cancer J, 2019, 9(4):44. doi: 10.1038/s41408-019-0205-9 pmid: 30962422
[2]	Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma[J]. Dtsch Arztebl Int, 2016, 113(27-28):470-476.
[3]	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. doi: 10.3322/caac.21387 URL
[4]	Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096 URL
[5]	Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma[J]. Ther Adv Hematol, 2018, 9(5):123-133. doi: 10.1177/2040620718761776 URL
[6]	Willenbacher E, Balog A, Willenbacher W. Short overview on the current standard of treatment in newly diagnosed multiple myeloma[J]. Memo, 2018, 11(1):59-64. doi: 10.1007/s12254-018-0383-3 URL
[7]	van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future[J]. Blood, 2018, 131(1):13-29. doi: 10.1182/blood-2017-06-740944 URL
[8]	Quarona V, Ferri V, Chillemi A, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche[J]. Ann N Y Acad Sci, 2015, 1335:10-22. doi: 10.1111/nyas.12485 URL
[9]	Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38⁺ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma[J]. Blood, 2016, 128(3):384-394. doi: 10.1182/blood-2015-12-687749 pmid: 27222480
[10]	Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology[J]. Physiol Rev, 2008, 88(3):841-886. doi: 10.1152/physrev.00035.2007 pmid: 18626062
[11]	Sherbenou DW, Behrens CR, Su Y, et al. The development of potential antibody-based therapies for myeloma[J]. Blood Rev, 2015, 29(2):81-91. doi: 10.1016/j.blre.2014.09.011 pmid: 25294123
[12]	Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy[J]. Nat Rev Immunol, 2010, 10(5):317-327. doi: 10.1038/nri2744 pmid: 20414205
[13]	de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors[J]. J Immunol, 2011, 186(3):1840-1848. doi: 10.4049/jimmunol.1003032 URL
[14]	Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer[J]. Nat Rev Cancer, 2012, 12(4):278-87. doi: 10.1038/nrc3236 URL
[15]	Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma[J]. MAbs, 2015, 7(2):311-321. doi: 10.1080/19420862.2015.1007813 pmid: 25760767
[16]	Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking[J]. J Immunol, 2016, 197(3):807-813. doi: 10.4049/jimmunol.1501351 pmid: 27316683
[17]	Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma[J]. J Hematol Oncol, 2016, 9(1):51. doi: 10.1186/s13045-016-0283-0 URL
[18]	van de Donk NWCJ. Immunomodulatory effects of CD38-targeting antibodies[J]. Immunol Lett, 2018, 199:16-22. doi: 10.1016/j.imlet.2018.04.005 URL
[19]	Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma[J]. Front Immunol, 2018, 9:1228. doi: 10.3389/fimmu.2018.01228 pmid: 29915586
[20]	中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订)[J]. 中华内科杂志, 2020, 59(5):341-346.
[21]	Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1 URL
[22]	Lamb YN. Daratumumab: A Review in Combination thera-py for transplant-eligible newly diagnosed multiple myeloma[J]. Drugs, 2020, 80(14):1455-1464. doi: 10.1007/s40265-020-01385-x URL
[23]	Voorhees PM, Kaufman JL, Laubach J, et al. Daratumu-mab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood, 2020, 136(8):936-945. doi: 10.1182/blood.2020005288 pmid: 32325490
[24]	Voorhees P, Rodriguez C, Reeves B, et al. Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Grifin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Muliple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)[J]. Blood, 2018, 132:151. doi: 10.1182/blood-2018-151 URL
[25]	Bal S, Godby K, Chhabra S, et al. Impact of Autologous hematopoetic stem cell transplant (AHCT) on measurable residual disease(MRD) by next generation sequencing (NGS) in the setting of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) quadruplet induction[J]. Biol Blood Marrow Transplant, 2020, 26(3):S24.
[26]	Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial[J]. Lancet, 2020, 395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3 URL
[27]	Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma[J]. Cancer, 2019, 125(14):2364-2382. doi: 10.1002/cncr.32065 pmid: 30951198
[28]	Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma[J]. N Engl J Med, 2019, 380(22):2104-2115. doi: 10.1056/NEJMoa1817249 URL
[29]	郭怀鹏, 康蕾, 刘聪, 等. Daratumumab在新诊断不适合移植及复发难治多发性骨髓瘤治疗的Meta分析[J]. 临床血液学杂志, 2021, 34(11):795-801,806.
[30]	刘进, 何海燕, 李璐, 等. 达雷妥尤单抗治疗复发/难治多发性骨髓瘤的疗效与安全性[J]. 中华血液学杂志, 2021, 42(1):27-32.
[31]	Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumu-mab plus bortezomib, melphalan, and prednisone for untreated myeloma[J]. N Engl J Med, 2018, 78(6):518-528.

达妥木单抗在多发性骨髓瘤一线治疗中的应用进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马雪菲, 王学锋, 王侃侃. 浆细胞瘤变异体易位1和MYC基因在泛癌中的表达及生存期预测价值分析[J]. 诊断学理论与实践, 2022, 21(04): 490-496.
[2]	陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528.
[3]	赵建治, 糜坚青. 多发性骨髓瘤相关生物标志物的研究进展[J]. 诊断学理论与实践, 2021, 20(05): 507-511.
[4]	范春丽, 吴涛, 薛锋, 胡文雪, 王存邦, 白海. MUM1/IRF4阳性弥漫大B细胞淋巴瘤一例治疗报告并文献复习[J]. 诊断学理论与实践, 2021, 20(04): 399-400.
[5]	彭真萍, 项喜喜, 张苏江, 李佳明. 以类白血病反应为首发表现的慢性中性粒细胞白血病二例并文献复习[J]. 诊断学理论与实践, 2020, 19(02): 122-128.
[6]	陆弘逾, 曹亚峰, 顾俊, 王静, 陈梅, 宋陆茜. 神经电生理检查对多发性骨髓瘤患者硼替佐米治疗相关周围神经病的预测及诊断意义[J]. 诊断学理论与实践, 2019, 18(06): 640-644.
[7]	侯健, 刘进. 2017年欧洲肿瘤内科学会多发性骨髓瘤的指南更新解读[J]. 诊断学理论与实践, 2017, 16(05): 455-459.
[8]	曹亚峰, 王静, 顾俊, 陆弘逾, 许杰, 刘元坊, 王焰, 王瑾, 陈钰, 陈玉宝, 李佳明, 郝杰, 糜坚青, 陈梅. 以硼替佐米为基础的联合方案治疗114例初诊多发性骨髓瘤患者的周围神经病变分析[J]. 诊断学理论与实践, 2017, 16(05): 492-497.
[9]	汪萍, 沈立松, 张冬青. 多发性骨髓瘤及相关疾病的实验室诊断认识[J]. 诊断学理论与实践, 2017, 16(05): 477-483.
[10]	李晓帆, 王少元. 多发性骨髓瘤微小残留病检测及其临床应用[J]. 诊断学理论与实践, 2017, 16(05): 472-476.
[11]	糜坚青, 金诗炜. 多发性骨髓瘤细胞分子遗传学异常与预后分层、治疗[J]. 诊断学理论与实践, 2017, 16(05): 460-463.
[12]	彭奕冰, 章黎华. 免疫球蛋白游离轻链的检测与临床应用[J]. 诊断学理论与实践, 2017, 16(05): 468-471.
[13]	王敏敏, 颜敏超, 郭晓珺. 硼替佐米和沙利度胺治疗多发性骨髓瘤致相关周围神经病变机制[J]. 诊断学理论与实践, 2016, 15(06): 629-631.
[14]	周盈盈, 周桢源, 黄新芳, 沈南,. miR-363-3p促进人浆细胞样树突细胞干扰素α分泌的机制研究[J]. 诊断学理论与实践, 2014, 13(03): 255-259.
[15]	刘占云, 王艳煜, 俞娇, 陈秋生, 李军民, 赵维莅,. 可溶性CD40在部分B细胞淋巴血液肿瘤患者中的表达及临床意义[J]. 诊断学理论与实践, 2012, 11(06): 620-623.